Mike Hollan

In this first part of this roundtable discussion, experts discuss the current perception of AI and how this is impacting adoption.

The report gives high rankings to brands from Pfizer and AstraZeneca.

EVERSANA’s chief digital officer discusses the current relationship between pharma and AI.

The musician launched the Get Low #2 campaign.

The non-profit’s new CEO discusses her role and how she plans to steer the organization towards the future.

The devices are being provided based on a variety of health-based features that they provide.

AIX exchanged key assets in exchange for ownership shares.

The two companies will work to develop treatments for SBMA.

CelloType produces more accurate results when analyzing high content tissue images.

The educational platform is targeted at HCPs and their staff.

The actor is part of a campaign for early colon cancer screening.

The results say that the industry still lacks talent and skills in this area.

The campaign also includes partnerships with other celebrities, including Lance Bass and Retta.

Dorman previously served as head of Gilead Sciences’ U.S. Oncology Unit.

The drug, developed by UCB, is approved to treat adults with the inflammatory skin disease.

Syndax describes the drug as the first of its kind.

The news is part of the organization’s goal of demonstrating a commitment to women’s health.

The contest focused on telling the stories of how migraines impacted patients’ careers.

Etira’s CEO discusses recent developments in R&D and with the company’s leadership.

A look at one biotech’s mission to map the immune system using artificial intelligence—and how its growth as a Big Pharma partner could help unlock the potential of next-generation cancer treatments.

Ann Beliën, PhD, founder and CEO of Rejuvenate Biomed, discusses how AI is being used to find new ways to treat age-related conditions.

The Jazz Pharmaceutical president and COO discusses her approach to the role and how it plays into the company’s overall goals.

The survey is part of an initiative from GSK to improve these gaps.

The company will also change its NASDAQ ticker to ONC.

Pleio’s chief experience officer discusses why these platforms are being embraced by the industry.

Decisions and strategies related to remote work, AI, and DE&I are especially evolving.

EVERSANA's Ryan discusses the company’s recent expansion into new markets in Europe.

Phesi’s founder and president discusses methods of improving the site selection process.

Familial Chylomicronemia Syndrome is a rare condition that can have deadly symptoms.

The campaign is focused on providing guidance for newly diagnosed patients.